Drugs / Tradipitant
Drug research

Tradipitant

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Nereus; VLY-686

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)NCT04140695Vanda PharmaceuticalsPhase 3Terminated2020-10-14Actual
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisNCT04028492Vanda PharmaceuticalsPhase 3Completed2025-02-21Actual
Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisNCT02651714Vanda PharmaceuticalsPhase 2Completed2017-08-04Actual
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)NCT03568331Vanda PharmaceuticalsPhase 3Completed2019-12-27Actual
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT06138613Vanda PharmaceuticalsPhase 3Active not recruiting2027-09-30Estimated
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessNCT05903924Vanda PharmaceuticalsPhase 3Completed2024-04-06Actual
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT04327661Vanda PharmaceuticalsPhase 3Completed2023-04-01Actual
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseNCT07446439Vanda PharmaceuticalsPhase 3Recruiting2026-12-01Estimated
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisNCT06836557Vanda PharmaceuticalsPhase 3Recruiting2025-12Estimated
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessNCT03772340Vanda PharmaceuticalsPhase 2Completed2019-06-06Actual
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseNCT06804603Vanda PharmaceuticalsPhase 2Completed2025-10-06Actual

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.